TradingMenu expanded
Forge Markets Forge Pro Browse Companies
DataMenu expanded
Forge Data Private Market Index Forge Accuidity Index IPO Stock Tracker
SolutionsMenu expanded
For Institutions For Shareholders For Investors For Companies In Europe
InsightsMenu expanded
All Insights Blog Glossary Reports Videos Webinars
Popular Topics
Buying Pre-IPO Shares Selling Pre-IPO Shares Private Market Updates Forge Investment Outlook Startup News Tech IPO Calendar for 2024
AboutMenu expanded
About Us Team Investor Relations People & Culture Careers FAQs
Log In Sign Up
Trading Menu expandedTrading
Forge Markets
Forge Pro
Browse Companies
Data Menu expandedData
Forge Data
Private Market Index
Forge Accuidity Index
IPO Stock Tracker
Solutions Menu expandedSolutions
For Institutions
For Shareholders
For Investors
For Companies
In Europe
Insights Menu expandedInsights
All Insights
Blog
Glossary
Reports
Videos
Webinars
Popular Topics
Buying Pre-IPO Shares
Selling Pre-IPO Shares
Private Market Updates
Forge Investment Outlook
Startup News
Tech IPO Calendar for 2024
About Menu expandedAbout
About Us
Team
Investor Relations
People & Culture
Careers
FAQs
Trading / Browse Private Companies / Aktis Oncology Stock

Aktis Oncology Stock

aktisoncology.comHealthcare / BioTech & PharmaFounded: 2019

Aktis Oncology is a biopharma solutions company that specializes in cancer care with novel platform technologies. Aktis Oncology uses powerful, radiopharmaceuticals to target therapies that harness alpha-emitting participles designed to optimize treatment options.

Buy or sell Aktis Oncology stockLearn more about Aktis Oncology IPO

Register To Buy and Sell Shares

For more details on financing and valuation for Aktis Oncology, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Aktis Oncology’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Aktis Oncology.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Aktis Oncology investors also invested in these private companies

Bristol Myers Squibb
MPM Capital
Octagon Capital Advisors
VIDA Ventures
Novartis
TCG

Team

Management Team

Matthew Roden, PhD
President & Chief Executive Officer
Paul L. Feldman, PhD
Chief Scientific Officer
Pankaj Bhargava, MD
Interim Chief Medical Officer
Brian Goodman, PhD
Co-Founder & Chief Operating Officer
Ved Srivastava, PhD
Vice President, Head of Chemistry
Karen McCarthy
Executive Director, Head of Finance
Tyler Benedum, PhD
Senior Vice President, Head of Chemistry, Manufacturing, and Controls
Dasa Lipovsek, PhD
Vice President, Head of Lead Discovery
Kelly Polanco
Vice President, Head of People & Culture
Carlos Rodriguez
Executive Director, Corporate Development
Lorraine Horgan
Executive Director, Head of Program Management
Janet Horton, MD
Executive Director, Clinical Development

Board Members

Todd Foley
MPM Capital
Helen Kim, MBA
Vida Ventures
Oleg Nodelman
EcoR1 Capital
Lloyd M. Segal, MBA
Repare Therapeutics

Frequently Asked Questions About Aktis Oncology’s Stock

plusminus
Can you buy Aktis Oncology’s stock?
Aktis Oncology is not publicly traded on NYSE or NASDAQ in the U.S. To buy Aktis Oncology’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Aktis Oncology’s stock?
Yes, you can sell stock of a private company like Aktis Oncology. Forge can help you sell your Aktis Oncology stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Aktis Oncology’s stock price?
Aktis Oncology is a privately held company and therefore does not have a public stock price. However, you may access Aktis Oncology’s private market stock price with Forge Data.
plusminus
What is Aktis Oncology’s stock ticker symbol?
Aktis Oncology does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Other companies like Aktis Oncology in the BioTech & Pharma sector

Egenesis

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$387.57MM

Colossal Biosciences

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.01B

Precision Neuroscience

Sector
Healthcare / BioTech & Pharma
 
 

Altos Labs

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$6.33B

Tempus

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$8.7B

BioAge

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$439.94MM

Pendulum Therapeutics

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$308.05MM

Life Biosciences

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$500MM

Cytonics

Sector
Healthcare / BioTech & Pharma
 
 

News Highlights

Crunchbase 09/06/2022
Aktis Oncology Nabs A Rare Upround of $84M In Extension Funding
Biotech firm Aktis Oncology announced Thursday it closed an $84 million extension round partially funded by large pharma companies like Merck, Bristol Myers Squibb and Novartis.

Trending Companies

Frequently Asked Questions

Updated on: Apr 19, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.